The Psychiatrist's Role in Tardive Dyskinesia

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

State of the Art in BRCA-Mutated Ovarian Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Current Management and Future Options for Tardive Dyskinesia

New Psoriasis Treatments

Why New Treatments for Schizophrenia Should Be on Your Radar

Applying Biosimilars in Hematologic Cancers

Advances in Managing Inhibitors in Patients With Hemophilia A

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

New Standards of Care in ALK-Translocated Advanced NSCLC

Mid-Year Hemophilia Update

Unmet Needs in Schizophrenia

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Management of CMV in HSCT Recipients

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Insights Into the Spectrum of Tardive Dyskinesia

Impactful Data in TD That Can Guide Treatment Decisions

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Locally Advanced Lung Cancer

Tackling Schizophrenia With Your Patients

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Patient Questions and Expert Answers in Psoriasis:

The Role of Maintenance Therapy in Multiple Myeloma

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

The Psychiatrist's Role in Tardive Dyskinesia

The ABCs of Diagnosing Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders.

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Presentation transcript:

The Psychiatrist's Role in Tardive Dyskinesia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

What Is TD?

Risk of TD With Antipsychotics

Risk Factors for TD

Preventing TD

Monitoring for Movement Disorders

Differential Diagnosis of TD

Initial Management of TD

Issues for Patients With Schizophrenia

Evidence for Various Therapies

VMAT2

Tetrabenazine

Valbenazine

KINECT 3: Phase 3 Trial of Valbenazine

Deutetrabenazine

Phase 3 Trials of Deutetrabenazine

Summary: Deutetrabenazine and Valbenazine

Takeaway Points

Abbreviations